Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

GlobeNewsWire • Feb 5, 2026

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne.

GlobeNewsWire • Feb 2, 2026

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

-  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study -  The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne -  New Drug Application for denifanstat (ASC40) for acne was recently accepted by the China National Medical Products Administration HONG KONG, Jan. 29, 2026 /PRNewswire/ --  Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, in patients with moderate-to-severe acne vulgaris. This recently completed second Phase III study was an open-label, multicenter study in China designed to evaluate the long-term safety of denifanstat (ASC40) in 240 patients with moderate to severe acne vulgaris.

PRNewsWire • Jan 29, 2026

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform

GlobeNewsWire • Jan 27, 2026

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah.

GlobeNewsWire • Jan 8, 2026

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market

Sagimet Biosciences Inc. remains a Strong Buy, driven by positive PK Denifanstat + Resmetirom combination data and advancing clinical programs in acne and MASH. SGMT's denifanstat plus resmetirom combo targets the untapped F4 MASH market, with phase 2 initiation anticipated in H2 2026 pending positive discussion with regulators. Ascletis' NDA acceptance in China for denifanstat in acne and SGMT's own TVB-3567 phase 1 progress strengthens the acne franchise.

Seeking Alpha • Dec 19, 2025

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1 pharmacokinetic (PK) trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom.

GlobeNewsWire • Dec 18, 2025

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience Co. Ltd. (Ascletis), of which Ascletis Pharma Inc. is the parent company.

GlobeNewsWire • Dec 10, 2025

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG , Dec. 10, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor for the treatment of moderate-to-severe acne vulgaris, has been accepted by the China National Medical Products Administration (NMPA).

PRNewsWire • Dec 10, 2025

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet's Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company's Series A common stock as determined based on the Black Scholes value on December 9, 2025, to be granted on December 9, 2025 to the three newly-hired employees.

GlobeNewsWire • Dec 9, 2025